MetaVia to Present Preclinical Data on Novel GPR119 Agonist at American Diabetes Association Conference

The a clinical-stage biotechnology company dedicated to transforming the treatment of cardiometabolic diseases MetaVia Inc. (Nasdaq: MTVA), announced that new preclinical data on its investigational drug DA-1241 has been accepted for presentation at the American Diabetes Association's (ADA) 85th Scientific Sessions. The conference will be held June 20-23, 2025, at McCormick Place Convention Center in Chicago, Illinois.

DA-1241 is a novel small molecule targeting G-Protein-Coupled Receptor 119 (GPR119), a receptor known to play a key role in glucose and lipid metabolism.

The abstract, titled "Additive Hepatoprotective Effects of DA-1241, a GPR119 Agonist, in Combination with Efruxifermin in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH," will be presented as a poster by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center. The presentation is scheduled for Sunday, June 22, during the Integrated Physiology--Liver session, from 12:30 to 1:30 p.m. CT.

The presented data will highlight DA-1241's potential to deliver additive hepatoprotective effects when combined with efruxifermin in preclinical models of metabolic dysfunction-associated steatohepatitis (MASH), a condition with rising global prevalence and limited therapeutic options.

Following the presentation, the poster will be accessible on the MetaVia website in the Posters section and will also be published online in the journal Diabetes(R).

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin ( OXM ) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor ( GCGR ) dual agonist . OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR , thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists . In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1 , GIP , and PYY . In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis , hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com .

This article contains sponsored content. See our disclaimer

The post MetaVia to Present Preclinical Data on Novel GPR119 Agonist at American Diabetes Association Conference appeared first on PRISM MarketView.

COMTEX_466081515/2927/2025-06-04T09:30:42